<?xml version='1.0' encoding='utf-8'?>
<document id="27541626"><sentence text="Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry."><entity charOffset="30-39" id="DDI-PubMed.27541626.s1.e0" text="pyrotinib" /></sentence><sentence text="Pyrotinib is a novel irreversible tyrosine kinase inhibitor developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer"><entity charOffset="0-9" id="DDI-PubMed.27541626.s2.e0" text="Pyrotinib" /><entity charOffset="34-42" id="DDI-PubMed.27541626.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.27541626.s2.e0" e2="DDI-PubMed.27541626.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27541626.s2.e0" e2="DDI-PubMed.27541626.s2.e1" /></sentence><sentence text=" The results of phase I clinical trial demonstrated that pyrotinib was well tolerated and exhibited potent antitumor activity"><entity charOffset="57-66" id="DDI-PubMed.27541626.s3.e0" text="pyrotinib" /></sentence><sentence text=" As a promising therapeutic agent for HER2-positive breast cancer, it is of great importance to investigate the biotransformation of pyrotinib in humans and identify the major enzymes involved in its metabolism during its early stage of development for safety consideration"><entity charOffset="133-142" id="DDI-PubMed.27541626.s4.e0" text="pyrotinib" /></sentence><sentence text=" For this purpose, a robust analytical method based on ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF MS) was established to characterize the metabolites of pyrotinib in human plasma, feces, and urine, and identify the primary enzymes responsible for its metabolism"><entity charOffset="206-215" id="DDI-PubMed.27541626.s5.e0" text="pyrotinib" /></sentence><sentence text=" As a result, a total of 24 metabolites were identified, including 16 phase I metabolites resulting from dealkylation, oxidation, dehydrogenation, and carbonylation, and 8 phase II metabolites originating from cysteine and N-acetylcysteine conjugation"><entity charOffset="210-218" id="DDI-PubMed.27541626.s6.e0" text="cysteine" /><entity charOffset="223-239" id="DDI-PubMed.27541626.s6.e1" text="N-acetylcysteine" /><pair ddi="false" e1="DDI-PubMed.27541626.s6.e0" e2="DDI-PubMed.27541626.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27541626.s6.e0" e2="DDI-PubMed.27541626.s6.e1" /></sentence><sentence text=" Pyrotinib was absorbed into blood by 1h, reached its peak level at 4h, and afterwards underwent slow elimination"><entity charOffset="1-10" id="DDI-PubMed.27541626.s7.e0" text="Pyrotinib" /></sentence><sentence text=" The principal metabolites detected in humans (M1, M2, and M5) were products resulting from O-depicoline and pyrrolidine lactam formation, whose structures have been confirmed by the synthetic references"><entity charOffset="92-104" id="DDI-PubMed.27541626.s8.e0" text="O-depicoline" /><entity charOffset="109-127" id="DDI-PubMed.27541626.s8.e1" text="pyrrolidine lactam" /><pair ddi="false" e1="DDI-PubMed.27541626.s8.e0" e2="DDI-PubMed.27541626.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27541626.s8.e0" e2="DDI-PubMed.27541626.s8.e1" /></sentence><sentence text=" In addition, fecal clearance was the major route of excretion for pyrotinib"><entity charOffset="67-76" id="DDI-PubMed.27541626.s9.e0" text="pyrotinib" /></sentence><sentence text=" Further phenotyping experiment proved that CYP3A4 was the most active enzyme responsible for the biotransformation of pyrotinib, implying the vital necessity of the assessment of the potential CYP3A-mediated drug-drug interactions in humans"><entity charOffset="119-128" id="DDI-PubMed.27541626.s10.e0" text="pyrotinib" /></sentence><sentence text=" Taken together, this study provided valuable metabolic data to explicate the dynamic process of pyrotinib in humans, and important reference basis for its safety evaluation and rational clinical application"><entity charOffset="97-106" id="DDI-PubMed.27541626.s11.e0" text="pyrotinib" /></sentence><sentence text=" The results will also benefit the assessment of the contributions to the overall activity or toxicity from the key metabolites" /><sentence text=" " /></document>